×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
GLUE – monte rosa therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
GLUE
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/30
04:41 am
glue
Monte Rosa: Looking Mispriced After Big Pharma Validation [Seeking Alpha]
Medium
Report
Monte Rosa: Looking Mispriced After Big Pharma Validation [Seeking Alpha]
11/8
02:14 pm
glue
Monte Rosa Therapeutics Presents Preclinical Data at AHA Scientific Sessions 2025 on the Potential of MRT-8102, a NEK7-directed Molecular Glue Degrader, to Treat Cardiovascular and Cardiometabolic Diseases [Yahoo! Finance]
High
Report
Monte Rosa Therapeutics Presents Preclinical Data at AHA Scientific Sessions 2025 on the Potential of MRT-8102, a NEK7-directed Molecular Glue Degrader, to Treat Cardiovascular and Cardiometabolic Diseases [Yahoo! Finance]
11/8
11:30 am
glue
Monte Rosa Therapeutics Presents Preclinical Data at AHA Scientific Sessions 2025 on the Potential of MRT-8102, a NEK7-directed Molecular Glue Degrader, to Treat Cardiovascular and Cardiometabolic Diseases
High
Report
Monte Rosa Therapeutics Presents Preclinical Data at AHA Scientific Sessions 2025 on the Potential of MRT-8102, a NEK7-directed Molecular Glue Degrader, to Treat Cardiovascular and Cardiometabolic Diseases
11/7
01:43 pm
glue
Monte Rosa Therapeutics (NASDAQ:GLUE) had its price target raised by analysts at Wells Fargo & Company from $10.00 to $13.00. They now have an "equal weight" rating on the stock.
Low
Report
Monte Rosa Therapeutics (NASDAQ:GLUE) had its price target raised by analysts at Wells Fargo & Company from $10.00 to $13.00. They now have an "equal weight" rating on the stock.
11/6
07:00 am
glue
Monte Rosa Therapeutics Announces Third Quarter 2025 Financial Results and Business Updates
Medium
Report
Monte Rosa Therapeutics Announces Third Quarter 2025 Financial Results and Business Updates
11/3
07:00 am
glue
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
Medium
Report
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
10/31
01:04 pm
glue
Monte Rosa Therapeutics (NASDAQ:GLUE) had its "sell (d+)" rating reaffirmed by analysts at Weiss Ratings.
Low
Report
Monte Rosa Therapeutics (NASDAQ:GLUE) had its "sell (d+)" rating reaffirmed by analysts at Weiss Ratings.
10/24
07:00 am
glue
Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2025 on the Potential of MRT-6160, a VAV1-directed Molecular Glue Degrader, to Treat Immune-mediated Diseases
Medium
Report
Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2025 on the Potential of MRT-6160, a VAV1-directed Molecular Glue Degrader, to Treat Immune-mediated Diseases
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Symbol
Headline
Impact
11/14
12:20 pm
glue
Form SCHEDULE 13G/A Monte Rosa Therapeutics, Filed by: PRICE T ROWE ASSOCIATES INC /MD/
Low
Report
Form SCHEDULE 13G/A Monte Rosa Therapeutics, Filed by: PRICE T ROWE ASSOCIATES INC /MD/
11/14
09:08 am
glue
Form SCHEDULE 13G/A Monte Rosa Therapeutics, Filed by: Avoro Capital Advisors LLC
Low
Report
Form SCHEDULE 13G/A Monte Rosa Therapeutics, Filed by: Avoro Capital Advisors LLC
11/12
04:13 pm
glue
Form SCHEDULE 13D/A Monte Rosa Therapeutics, Filed by: Versant Venture Capital VI, L.P.
Low
Report
Form SCHEDULE 13D/A Monte Rosa Therapeutics, Filed by: Versant Venture Capital VI, L.P.
11/6
07:05 am
glue
Form 10-Q Monte Rosa Therapeutics, For: Sep 30
Medium
Report
Form 10-Q Monte Rosa Therapeutics, For: Sep 30
11/6
07:03 am
glue
Form 8-K Monte Rosa Therapeutics, For: Nov 06
Medium
Report
Form 8-K Monte Rosa Therapeutics, For: Nov 06
10/31
11:04 am
glue
Form SCHEDULE 13G/A Monte Rosa Therapeutics, Filed by: VANGUARD GROUP INC
Low
Report
Form SCHEDULE 13G/A Monte Rosa Therapeutics, Filed by: VANGUARD GROUP INC
10/17
04:29 pm
glue
Form SCHEDULE 13G Monte Rosa Therapeutics, Filed by: TCG Crossover GP II, LLC
Low
Report
Form SCHEDULE 13G Monte Rosa Therapeutics, Filed by: TCG Crossover GP II, LLC
10/3
12:19 pm
glue
Form SCHEDULE 13G Monte Rosa Therapeutics, Filed by: Dimension Capital I, L.P.
Low
Report
Form SCHEDULE 13G Monte Rosa Therapeutics, Filed by: Dimension Capital I, L.P.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: